ASH2022注目テーマ⑥「Late-Breaking Abstracts Session #6」

CLLおよびSLLで
第二世代BTK阻害薬zanubrutinibの
有効性が示される Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study (#LBA-6)

Jennifer R. Brown（Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA）